株探米国株
日本語 英語
エドガーで原本を確認する
0001662579false00016625792025-05-072025-05-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________
FORM 8-K
_________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2025
_________________________________________________________________
C4 THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
_________________________________________________________________
Delaware 001-39567 47-5617627
(State or Other Jurisdiction
of Incorporation)
 (Commission File Number)
(IRS Employer
Identification No.)
490 Arsenal Way,   Suite 120
Watertown,  MA
 02472
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 231-0700
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.0001 par value per share CCCC The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o On May 7, 2025, C4 Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 


Item 2.02 Results of Operations and Financial Condition.
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 7.01 Regulation FD Disclosure.
On May 7, 2025, the Company posted a corporate presentation on its website at https://ir.c4therapeutics.com/events-presentations. A copy of the presentation is furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.
Item 8.01 Other Events.
On May 7, 2025, the Company provided the following updates from its Phase 1 clinical trial of cemsidomide:
•Phase 1 dose escalation is complete in multiple myeloma (“MM”) with the 100 μg once daily (“QD”) dose level declared safe for expansion; 10 additional patients will be treated in a 100 μg QD expansion cohort to further characterize cemsidomide’s safety and efficacy profile at this dose level.
•Cemsidomide MM topline data demonstrated compelling responses rates at multiple doses:
◦As of the data cutoff date of April 30, 2025, 10 patients have been treated at the 100 μg QD dose level, achieving an overall response rate (“ORR”) of 50 percent. Notably, one patient who previously progressed on two prior T-cell engager therapies achieved a minimal residual disease negative complete response (measured by flow cytometry). Eight patients (80 percent) treated at this dose level received prior CAR-T or T-cell engager therapy.
◦Since October 11, 2024, six additional patients have been treated for a total of 20 patients treated at the 75 μg QD dose level. As of the data cutoff date of April 30, 2025, the 75 μg QD dose level achieved an ORR of 40 percent.
◦Cemsidomide remains well-tolerated with manageable neutropenia.
•For the non-Hodgkin’s lymphoma arm, the Phase 1 dose escalation trial is ongoing at the 87.5 μg QD dose level and the maximum tolerated dose has not yet been reached.
•The Company expects to receive regulatory feedback on registrational development for cemsidomide by mid-year 2025 to support initiation of next phase of development in early 2026.
Forward-Looking Statements
This information under Item 8.01 of this Current Report on Form 8-K contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the Company’s ability to develop potential therapies for patients; the design and potential efficacy of the Company’s therapeutic approaches; the predictive capability of the Company’s TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC® degraders; the potential timing, design and advancement of the Company’s preclinical studies and clinical trials, including the potential timing for and receipt of regulatory advice or authorization related to clinical trials and other clinical development activities including clinical trial commencement or cohort initiation; the Company’s ability and the potential to successfully manufacture and supply its product candidates for clinical trials; the Company’s ability to replicate results achieved in preclinical studies or clinical trials in any future studies or trials; the Company’s ability to replicate interim or early-stage results from its clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from the Company’s clinical trials; and the Company’s ability to fund its future operations. Any forward-looking statements included under Item 8.01 of this Current Report on Form 8-K are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could


cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for the Company’s product candidates; the risk that any one or more of the Company’s product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund the Company’s future operations will be available on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in Item 8.01 of this Current Report on Form 8-K is as of the date of the filing, and the Company undertakes no duty to update this information unless required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.
Exhibit
Number
 Description
99.1
99.2
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
C4 Therapeutics, Inc.
Date: May 7, 2025
 By: /s/ Jolie M. Siegel
Jolie M. Siegel
Chief Legal Officer and Secretary

EX-99.1 2 cccc-20250507xexx991.htm EX-99.1 Document

Exhibit 99.1
c4tlogo1a.jpg

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level
Cemsidomide Multiple Myeloma Dose Escalation is Complete; FDA Feedback Expected by Mid-Year 2025 to Support Initiation of Next Phase of Development in Early 2026
Portfolio Decision to Prioritize Cemsidomide Development; C4T to Seek Partnership Opportunities to Advance BRAF Program
CFT8919 Phase 1 Trial Continues to Advance in Partnership with Betta Pharmaceuticals; Discovery Platform Achieves Two Preclinical Milestones Under the Roche Collaboration
Cash, Cash Equivalents and Marketable Securities of $234.7 Million as of March 31, 2025 Expected to Provide Runway Into 2027
WATERTOWN, Mass., May 7, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the first quarter ended March 31, 2025, as well as business updates.
“2025 has been marked by focused execution across C4T to generate key data to optimize development plans across our clinical portfolio. With cemsidomide demonstrating compelling overall response rates at multiple dose levels, including one multiple myeloma patient at 100 µg who achieved a minimal residual disease negative complete response, we are prioritizing progressing cemsidomide to the next phase of development to realize its potential to be a best-in-class IKZF1/3 degrader,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “With the achievement of two preclinical milestones in our Roche collaboration, we continue to demonstrate the productivity of our TORPEDO platform to discover highly catalytic, orally bioavailable, and brain penetrant degraders. We remain focused on maximizing our cash runway, which includes advancing cemsidomide and pursuing our internal discovery pipeline focused on targets with a clear degrader rationale and compelling biology applicable to a broad range of therapeutic areas.”
FIRST QUARTER 2025 HIGHLIGHTS AND RECENT ACHIEVEMENTS
Cemsidomide:
•Phase 1 dose escalation is complete in multiple myeloma (MM) with the 100 µg once daily (QD) dose level declared safe for expansion; 10 additional patients will be treated in a 100 µg QD expansion cohort to further characterize cemsidomide’s safety and efficacy profile at this dose level.
•Cemsidomide MM topline data demonstrate compelling responses rates at multiple doses:
◦As of the data cutoff date of April 30, 2025, 10 patients have been treated at the 100 µg QD dose level, achieving an overall response rate (ORR) of 50 percent. Notably, one patient who previously progressed on two prior T-cell engager therapies achieved a minimal residual disease (MRD) negative complete response (measured by flow cytometry).


Eight patients (80 percent) treated at this dose level received prior CAR-T or T-cell engager therapy.
◦Since October 11, 2024, six additional patients have been treated for a total of 20 patients treated at the 75 µg QD dose level. As of the data cutoff date of April 30, 2025, the 75 µg QD dose level achieved an ORR of 40 percent.
◦Cemsidomide remains well-tolerated with manageable neutropenia.
•For the non-Hodgkin’s lymphoma (NHL) arm, the Phase 1 dose escalation is ongoing at the 87.5 µg QD dose level and the maximum tolerated dose has not yet been reached.
•C4T expects to receive regulatory feedback on registrational development by mid-year 2025.
CFT1946:
•Phase 1 dose escalation is complete with 640 mg BID declared as the maximum administered dose. Across the trial, which includes the dose escalation, melanoma and colorectal cancer cohorts, 89 patients were treated.
•The pharmacodynamic and safety data, including the data presented at the European Society for Medical Oncology (ESMO) Congress 2024, supports proof of mechanism and the therapeutic potential of degrading the BRAF V600 mutant protein.
•Given emerging clinical data and the company’s focus on strategic capital allocation, C4T will not advance CFT1946 beyond the ongoing Phase 1 trial. C4T has made the decision to seek partnership opportunities to advance the BRAF program given the high unmet need and strong degrader rationale for treating BRAF V600 mutant solid tumors.
•The CFT1946 Phase 1 data will be presented at a future medical meeting.
CFT8919:
•Partner Betta Pharmaceuticals continues to advance the CFT8919 Phase 1 dose escalation trial in Greater China.
Research and Discovery Collaborations:
•Advanced Roche collaboration to preclinical milestones. In March 2025, C4T earned a total of $4 million in payments upon achieving certain preclinical milestones for two programs. C4T and Roche continue to advance these programs.
•C4T continues to advance its internal research pipeline focused on targets in therapeutic areas in and beyond oncology with a strong degrader rationale and genetic link to disease.
KEY UPCOMING MILESTONES
•Present data from completed cemsidomide Phase 1 dose escalation in MM in Q3 2025.
•Complete cemsidomide Phase 1 dose escalation in NHL and present data in Q4 2025.
•Open expansion cohort(s) in PTCL as part of the current cemsidomide Phase 1/2 trial in the second half of 2025.
•Enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026.



UPCOMING INVESTOR EVENTS
•June 4, 2025: Management will participate in the Jefferies Global Healthcare Conference taking place from June 3 – June 5, 2025 in New York, New York.
FIRST QUARTER 2025 FINANCIAL RESULTS
Revenue: Total revenue for the first quarter of 2025 was $7.2 million, compared to $3.0 million for the first quarter of 2024. The increase in revenue was primarily due to our collaborations with Merck KGaA, Darmstadt, Germany (MKDG), which commenced in March 2024, as well as our achievement of two preclinical milestones under our Roche collaboration.
Research and Development (R&D) Expense: R&D expense for the first quarter of 2025 was $27.1 million compared to $22.5 million for the first quarter of 2024. The increase in R&D expense was primarily related to clinical trial expenses for cemsidomide and CFT1946, in addition to increased preclinical spend as our research collaborations continue to advance.
General and Administrative (G&A) Expense: G&A expense for the first quarter of 2025 was $9.3 million compared to $10.3 million for the first quarter of 2024. The decrease was primarily a result of reduced personnel costs related to our 2024 restructuring activities.
Net Loss and Net Loss per Share: Net loss for the first quarter of 2025 was $26.3 million, compared to $28.4 million for the first quarter of 2024. Net loss per share for the first quarter of 2025 was $0.37 compared to $0.41 for the first quarter of 2024.
Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities as of March 31, 2025 were $234.7 million, compared to $267.3 million as of December 31, 2024. The decrease was primarily the result of cash used in operating activities. The balance as of March 31, 2025 is exclusive of the $4.0 million in milestones earned under our Roche collaboration, which the company expects to receive in the second quarter of 2025. The company expects that its cash, cash equivalents and marketable securities as of March 31, 2025 will enable the company to fund its operating plan into 2027.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About Cemsidomide
Cemsidomide is an investigational, orally bioavailable small-molecule degrader designed to be a more potent and selective degrader of IKZF1/3, transcription factors that drive multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), with unique pharmacokinetic properties. Clinical data has shown that cemsidomide is well-tolerated. In MM, cemsidomide displays evidence of anti-myeloma activity and immunomodulatory effects. In NHL, cemsidomide displays evidence of anti-lymphoma activity. More information may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).


About CFT1946
C4T has advanced preclinical and clinical research to explore how targeted protein degradation may offer improvement over approved therapies that inhibit mutant BRAF V600. C4T advanced CFT1946, an investigational, orally bioavailable brain penetrant small molecule degrader of BRAF V600 mutations in solid tumors into a Phase 1/2 global clinical trial in patients refractory to BRAF inhibitors. CFT1946 is designed to be potent and selective against the BRAF V600 mutant form. In May 2025, C4T announced the decision to not advance its BRAF program beyond the current Phase 1 trial of CFT1946 and seek partnership opportunities to maximize its potential given the high unmet need and strong degrader rationale for treating BRAF V600 mutant solid tumors.
About CFT8919
CFT8919 is an orally bioavailable allosteric degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M and L858R-T790M-C797S. C4T and Betta Pharmaceuticals have established a strategic partnership to develop CFT8919 in Greater China, where the Phase 1 clinical trial is underway. C4T retains development and commercialization rights for CFT8919 in the United States, European Union and rest of the world.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC® degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory advice or authorization related to clinical trials and other clinical development activities including clinical trial commencement or cohort initiation; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to replicate interim or early-stage results from our clinical trials in the results obtained when those clinical trials are completed or when those therapies complete later-stage clinical trials; regulatory developments in the United States and foreign countries; the anticipated timing and content of presentations of data from our clinical trials; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.



Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com


Condensed Consolidated Balance Sheet Data 
(in thousands) 

March 31, 2025 December 31, 2024
Cash, cash equivalents and marketable securities $ 234,706  $ 267,263 
Total assets 319,524  349,602 
Deferred revenue 46,702  47,169 
Total stockholders' equity 195,140  215,986 
 Condensed Consolidated Statements of Operations 
(in thousands, except share and per share amounts)
Three Months Ended March 31,
2025 2024
Revenue from collaboration agreements $ 7,238  $ 3,039 
Operating expenses:
Research and development 27,072  22,533 
General and administrative 9,330  10,288 
Restructuring —  2,437 
Total operating expenses 36,402  35,258 
Loss from operations (29,164) (32,219)
Other income, net
Interest and other income, net 2,842  3,858 
Total other income, net 2,842  3,858 
Net loss $ (26,322) $ (28,361)
Net loss per share - basic and diluted $ (0.37) $ (0.41)
Weighted-average number of shares - basic and diluted 70,833,044  68,432,168 


EX-99.2 3 maycorporatedeck_finalx5.htm EX-99.2 maycorporatedeck_finalx5
Protein degraded. Disease targeted. Lives transformed. May 2025

 
Forward-looking Statements and Intellectual Property FORWARD-LOOKING STATEMENTS The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.’s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise. This presentation also contains estimates, projections and other information concerning the markets for C4 Therapeutics, Inc.’s product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions and patient use of medicines. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, and circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, from other publicly available information, and from government data and similar sources. INTELLECTUAL PROPERTY C4 Therapeutics, Inc. owns various registered and unregistered trademarks and service marks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols ®, SM and , but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to. © 2025 C4 Therapeutics, Inc. 2

 
Our Mission To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients’ lives. Our portfolio of degrader medicines pursues targets that may benefit from a degrader approach: Cemsidomide targeting IKZF1/3 for multiple myeloma and non-Hodgkin’s lymphoma CFT8919 targeting EGFR L858R for non-small cell lung cancer CFT19461 targeting BRAF V600 mutant for solid tumors including melanoma & colorectal cancer Internal Discovery Pipeline targets in therapeutic areas in and beyond oncology with a strong degrader rationale and genetic link to disease 3 1CFT1946 Phase 1 trial is ongoing. C4T will not advance CFT1946 beyond the Phase 1 trial

 
C4T Has Been at the Forefront of TPD Science and Is On the Path to Becoming a Fully Integrated Biotechnology Company © 2025 C4 Therapeutics, Inc. Built TORPEDO platform to design highly catalytic, orally bioavailable degraders Established collaborations with leading global pharmaceutical companies, building expertise across a range of diseases and target classes Assembled strong catalog of intellectual property Progressed four development candidates into the clinic with three clinical trials ongoing Delivered two development candidates to a collaborator for non-oncology targets Achieved blood-brain barrier penetration in several development candidates Advancing clinical programs to approval for patients with high unmet needs Leveraging TORPEDO platform to develop a sustainable pipeline against targets with a strong degrader rationale and genetic link to disease in therapeutic areas in and beyond oncology Expanding application of targeted protein degradation through high-value collaborations Leading the Way in Designing Orally Bioavailable Degraders 2015 – 2020 Delivering on the Promise of Targeted Protein Degradation 2025 and beyond Demonstrating Proof of Concept 2020 – 2025 4 MM cemsidomide data presented in December 2024 at ASH

 
PROGRAM TARGET INDICATIONS RESEARCH PRECLINICAL EARLY DEVELOPMENT LATE DEVELOPMENT RIGHTS Cemsidomide IKZF1/3 Multiple Myeloma & Non-Hodgkin’s Lymphoma CFT89191 EGFR L858R Non-Small Cell Lung Cancer CFT19462 BRAF V600 Mutant V600 Mutant Cancers Discovery Programs Oncology & Non-oncology indications 1 License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China 2 In May 2025, C4T announced CFT1946 will not advance beyond Phase 1 and that the company will seek partnership for the BRAF program © 2025 C4 Therapeutics, Inc. MM NHL Focused Pipeline to Advance a Portfolio of Degrader Medicines Targeting Areas of High Unmet Need 5 Colorectal Cancer Other BRAF V600 Mutant Cancers Melanoma

 
Prioritized Portfolio with Multiple 2025 Milestones © 2025 C4 Therapeutics, Inc. Cemsidomide IKZF1/3 2Q 2025: Completed Phase 1 dose escalation in MM 3Q 2025: Present data from completed Phase 1 dose escalation in MM 4Q 2025: Complete Phase 1 dose escalation in NHL and present data 2H 2025: Open expansion cohort(s) in PTCL in the ongoing Phase 1/2 trial 2025: Enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026 CFT8919 EGFR L858R Year-end 2025: Utilize data from Phase 1 dose escalation trial in Greater China to inform ex-China clinical development 2Q 2025: Advanced two programs to preclinical milestones through the Roche collaboration 2025: Present and publish preclinical work from internal pipeline and TORPEDO platform 2025: Advance internal and collaboration programs to key discovery milestones Discovery Multiple myeloma (MM); peripheral T-cell lymphoma (PTCL), a subtype of NHL 6 2Q 2025: Complete monotherapy Phase 1 dose escalation trial in BRAF V600 mutant solid tumors 2Q 2025: Generate data from Phase 1 cohorts evaluating CFT1946 as a monotherapy in melanoma, in combination with trametinib in melanoma, and in combination with cetuximab in CRC to define and enable next phase of development CFT1946 BRAF V600 Mutant

 
Advancing Oncology and Non-oncology Discovery Programs with Collaboration Partners © 2025 C4 Therapeutics, Inc. Evaluating targets in autoimmune diseases & oncology Advanced two programs to preclinical milestones Discovering targeted protein degraders against critical oncogenic proteins Discovering and developing degrader antibody conjugates in oncology Delivered two development candidates for non-oncology targets1 1Delivered development candidates to Biogen in Q1 2024 and Q3 2024 7

 
Cemsidomide IKZF1/3 Degrader Multiple Myeloma & Non-Hodgkin’s Lymphoma

 
IKZF1/3 Are Key Promoters of Myeloma and Lymphoma Cell Survival and Will Remain Important Therapeutic Targets for These Indications Multiple myeloma (MM); non-Hodgkin’s lymphoma (NHL) Hematopoietic Stem Cell Common Myeloid Progenitor Cell Common Lymphoid Progenitor Cell Neutrophil Platelets T-Cell B-Cell Plasma Cell Oncogenic Mutations/Aberrations T-Cell Lymphoma B-Cell Lymphoma Multiple Myeloma IKZF1/3 IRF4 ↑ IKZF1/3 and IRF4 Key Roles of IKZF1/3: • Multiple myeloma and lymphoma cells rely on IKZF1/3 and IRF4 for survival • Degrading IKZF1/3 leads to down regulation of IRF4, promoting myeloma and lymphoma cell death and on-target neutropenia • IKFZ1/3 degradation combined with MM immune-based regimens have potential to enhance activity through T-cell activation and cancer cell death by downregulation of IRF4 Advantages of Cemsidomide: Cemsidomide is more potent than approved and development stage IKZF1/3 degraders Increased selectivity for IKZF1/3 resulting in reduced off-target toxicity © 2025 C4 Therapeutics, Inc. 9 Multiple Myeloma

 
Cemsidomide Dose Escalation Is Complete With 100 µg QD Dose Level Declared Safe; Patients Enrolling in the Expansion Cohort at this Dose Level DL 5 (100 µg QD) DL 4 (75 µg QD) DL 3 (62.5 µg QD) DL 2 (37.5 µg QD) DL 1 (50 µg MWF) Expansion cohorts DOSE ESCALATION CEMSIDOMIDE 14/14 + DEX* Utilizing a Bayesian logistic regression model until determination of the MTD and/or RP2D © 2025 C4 Therapeutics, Inc. KEY INCLUSION CRITERIA • Adults with MM, R/R to at least 3 prior lines of therapy that have included lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid, and an anti-CD38 monoclonal antibody • Nonresponsive to or progressed within 60 days of prior therapy • Creatinine clearance ≥40 mL/min • ECOG ≤2 Phase 1 Study Endpoints • Primary: assess safety, tolerability and define the RP2D/MTD • Secondary: assess PK, PD, and preliminary anti-tumor activity *Cemsidomide administered as 14 days on/14 days off in a 28-day cycle; Dex was dosed on days 1, 8, 15, and 22 at doses of 40 mg orally for patients ≤75 years old and 20 mg orally for patients >75 years old; 2 patients at 100 µg are excluded as they had not completed Cycle 1 as of the data cut off date. Eastern Cooperative Oncology Group (ECOG); maximum tolerated dose (MTD); Monday Wednesday Friday (MWF); multiple myeloma (MM); once daily (QD); pharmacodynamics (PD); pharmacokinetic (PK); recommended Phase 2 dose (RP2D); relapsed refractory (R/R) 10 • 10 additional patients will enroll in the 100 µg QD expansion cohort to further characterize cemsidomide’s profile Multiple Myeloma

 
TEMRA TEM 0 20 40 60 80 100 % positive cells (C1D21 vs C1D1) % p o s it iv e c e ll s C1D1 C1D21 © 2025 C4 Therapeutics, Inc. Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy ** **** TEMRA: Terminally differentiated T-cells TEM: Effector memory T-cells Peripheral blood mononuclear cells (PBMCs); daily dosing (QD); Monday, Wednesday, Friday dosing (MWF); multiple myeloma (MM) Source: C4T data on file as of 11/28/2023 (https://ir.c4therapeutics.com/static-files/ec59b02e-3074-484d-ad88-e81831bf37ed) • 19 patient samples (PBMCs) analyzed by flow cytometry • Aggregate data of 25 µg, 50 µg, and 75 µg Supports potential of cemsidomide as a maintenance therapy option and in combination with other MM agents to improve efficacy: ✓ Cemsidomide induces CD8+ T- cell activation by increasing effector memory T-cell subset ✓ T-cell activation is observed at well-tolerated monotherapy clinical doses ✓ Clinical data consistent with the preclinical in vitro data reported for cemsidomide Multiple Myeloma 11

 
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate its Potential to Have a Best-in-Class Profile 12© 2025 C4 Therapeutics, Inc. Cemsidomide continued to be well-tolerated with manageable neutropenia1 0% 25% 50% 75% 100% All Dose Cohorts (N=63) 75 µg Cohort (N=20) 100 µg Cohort (N=10) R e sp o n se R a te ORR 33% ORR 40% ORR 50% Compelling anti-myeloma activity observed across multiple doses1 1. Data cut-off date as of April 30,2025; C4T data on file Data presented at ASH with data cutoff date as of 10/11/24, can be found here: https://ir.c4therapeutics.com/static-files/32ae4fdb-d4d9-4a17-a77d-83289c66e91f Overall Response Rate (ORR); minimal residual disease (MRD); complete response (CR); once daily (QD) Cemsidomide +Dex - Overall Response Rates Multiple Myeloma At the 100 µg dose level: • One patient achieved an MRD negative CR • Eight patients (80%) received prior CAR-T or T-cell engager therapy

 
Cemsidomide Has the Potential to Become a Treatment Option Across Lines of Therapy and Address a Growing Relapsed Refractory Patient Population 2L ~56,000 1L ~65,000 3L ~49,000 4L ~42,000 5L+ ≥23,000 U.S. + EU4 + UK Addressable Patients (2024)1 Treatment Line Phase 1/2 (Escalation/Expansion) Cemsidomide/Dex + Anti-CD38 and Cemsidomide + BCMA Bispecific Phase 2 (Single Arm) Cemsidomide + Dex (Post anti-BCMA) Randomized Phase 3 Cemsidomide/Dex + Anti-CD38 (2-4 prior lines; post anti-BCMA) Randomized Phase 3 Cemsidomide + BCMA Bispecific (1-3 prior lines) Studies Currently Being Enabled Studies for Registrational Intent Potential Accelerated Approval INITIAL CEMSIDOMIDE DEVELOPMENT PATH IN MM 1 EvaluatePharma (accessed 1/8/25), consulting engagements with Health Advances and Clearview. Germany, Italy, France, and Spain (EU4). B-cell maturation antigen (BCMA); dexamethasone (Dex); T-Cell engager (TCE); multiple myeloma (MM) Multiple Myeloma © 2025 C4 Therapeutics, Inc. Development Rationale Potentially enhances response durability and treatment duration of BCMA bispecific by preventing T-cell exhaustion Provides post anti-BCMA patients a potentially highly efficacious combo where there are limited proven options Potential to provide highly refractory patients a treatment option that is tolerable and efficacious where there are limited options 13

 
With a Potential Best-in-Class Profile, Cemsidomide Is Positioned to Be an IKZF1/3 Degrader of Choice Across Various Combinations Post-Transplant Maintenance1 Anti-CD38 Combos Proteasome Inhibitor Combos CAR-Ts (+/- Maintenance Therapy) Other MOAs2 1Approximately 30% of multiple myeloma patients undergo a hematopoietic stem cell transplant and receive post-transplant maintenance therapy. 2 Other MOAs approved in MM include dexamethasone combos, anti-SLAMF7 mAbs and XPO1 inhibitors. Potential future treatment options include FcRH5 bispecific T-cell engagers, BCL-2 inhibitors, and others. Sources: EvaluatePharma (accessed 1/8/25), NCCN guidelines, consulting engagements with Health Advances and Clearview. B-cell maturation antigen (BCMA); dexamethasone (dex); G protein-coupled receptor, class C, group 5, member D (GPRC5D); monoclonal antibodies (mAbs); mechanism of action (MOA); Germany, Italy, France, and Spain (EU4) BCMA/GPRC5D T-cell Engagers and ADC Combos © 2025 C4 Therapeutics, Inc. CEMSIDOMIDE OPPORTUNITY • Potential to address a growing patient population as current 5L+ treatment options start to be used in earlier lines • Cemsidomide has the potential to become the IKZF1/3 degrader of choice in numerous regimens across lines of therapy given its potent anti-myeloma activity, differentiated safety profile, and immunomodulatory effects • Cemsidomide has the potential to achieve peak annual revenues of ~$1B as a 5L+ treatment option +dex and over $6B if labels in combination with a BCMA bispecific and in combination with dex + an anti-CD38 are achieved EVOLVING MULTIPLE MYELOMA TREATMENT LANDSCAPE Multiple Myeloma 2L ~56,000 1L ~65,000 3L ~49,000 4L ~42,000 5L+ ≥23,000 U.S. + EU4 + UK Addressable Patients (2024) Treatment Line 14

 
Cemsidomide Phase 1 Dose Escalation Trial in NHL Continues to Progress © 2025 C4 Therapeutics, Inc. KEY INCLUSION CRITERIA • Adults with NHL, R/R to prior therapy • PTCL patients must have received at least 1 prior alkylator-based chemotherapy • ALCL patients must have also received a CD-30 mAb • Nonresponsive to or progressed within 60 days of prior therapy • Creatinine clearance ≥40 mL/min • ECOG ≤2 Phase 1 Study Endpoints • Primary: assess safety, tolerability and define the RP2D/MTD • Secondary: assess PK, PD, and preliminary anti-tumor activity DOSE ESCALATION CEMSIDOMIDE 14/14 Utilizing a Bayesian logistic regression model until determination of the MTD and/or RP2D 87.5 µg QD Potential to dose escalate back to 100 µg Anaplastic large cell lymphoma (ALCL); dose escalation meeting (DEM); dose limiting toxicities (DLT); Eastern Cooperative Oncology Group (ECOG); monoclonal antibody (mAb); maximum tolerated dose (MTD); Monday Wednesday Friday (MWF); non-Hodgkin’s lymphoma (NHL);once daily (QD); pharmacodynamic (PD); pharmacokinetic (PK); peripheral T-cell lymphoma (PTCL); recommended Phase 2 dose (RP2D); relapsed refractory (R/R) 75 µg QD 100 µg QD 62.5 µg QD 37.5 µg QD 50 µg QD 25 µg MWF NHL 15

 
Cemsidomide Was Well-tolerated With Manageable Incidents of On- target Neutropenia Common (>20% All Grades) TEAEs and Events of Interest*, n (%) All Grade (N=23) Grade 3 (N=23) Grade 4 (N=23) Infections Upper respiratory tract infection Sepsis Bacteremia Pneumonia 15 (65) 4 (17) 1(4) 1(4) 2 (9) 4 (17) 0 0 0 2 (9) 2 (9) 0 1 (4) 1 (4) 0 Neutropenia 11 (48) 4 (17) 7 (30) Fatigue 11 (48) 1 (4) 0 Cough 7 (30) 0 0 Anemia 6 (26) 4 (17) 0 Peripheral edema 5 (22) 0 0 Febrile neutropenia* 4 (17) 4 (17) 0 Thrombocytopenia* 4 (17) 1 (4) 2 (9) Maculopapular rash* 3 (13) 2 (9) 0 One patient experienced a Grade 5 AE (hip fracture resulting in transfer to hospice) • 2 DLTs occurred at 100 µg QD (Grade 4 thrombocytopenia and Grade 3 febrile neutropenia) • TEAEs leading to discontinuation: 9% (2/23) • 39% (9/23) of patients received G-CSF • 3 of 9 patients received G-CSF in Cycle 1 © 2025 C4 Therapeutics, Inc. *Events of Interest Adverse event (AE); dose limiting toxicities (DLTs); granulocyte colony-stimulating factor (G-CSF); once daily (QD); treatment emergent adverse events (TEAEs) Source: ASH 2024; C4T data as of 10/11/2024.(https://ir.c4therapeutics.com/static-files/32ae4fdb-d4d9-4a17-a77d-83289c66e91f) NHL 16

 
Compelling and Deep Responses Achieved Across PTCL Subtypes 19% (3) 25% (1) 20% (1) 20% (1) 25% (4) 75% (3) 50% (1) 0% 25% 50% 75% 100% All PTCL (N=16) AITL (N=4) ALCL (N=2) ATLL (N=5) PTCL-NOS (N=5) B e st R e sp o n se % ( N ) CMR PMR PET-CT–based Assessment of PMR or Better by PTCL Subtype* (N=16) ORR 20% ORR 20% ORR 100% ORR 50% © 2025 C4 Therapeutics, Inc. ORR 44% *Investigator assessed response; 2 patients were evaluated based on CT scan and were PD but not evaluable based on PET-CT, both patients are included as PMD for PET-CT based assessment; 2 additional subjects that came off study prior to follow up scans were not considered efficacy evaluable. Angioimmunoblastic T-cell lymphoma (AITL); anaplastic large cell lymphoma (ALCL); adult T-cell lymphoma (ATLL); complete metabolic response (CMR); overall response rate (ORR); partial metabolic response (PMR); peripheral T- cell lymphoma (PTCL); peripheral T-cell lymphoma not-otherwise specified (PTCL-NOS) Source: ASH 2024; C4T data as of 10/11/2024.(https://ir.c4therapeutics.com/static-files/32ae4fdb-d4d9-4a17-a77d-83289c66e91f) • Cemsidomide monotherapy produced responses in all four PTCL subtypes • All AITL patients (4/4) experienced a metabolic response NHL 17

 
Cemsidomide NHL Data Supports Further Development in PTCL, Which Provides the Fastest Path to Market Phase 2 (Single Arm) Cemsidomide Monotherapy (2L+ R/R PTCL) Randomized Phase 3 Cemsidomide + SOC2 (treatment naïve) Study Currently Being Enabled Study for Registrational Intent Potential Accelerated Approval INITIAL CEMSIDOMIDE DEVELOPMENT PATH IN PTCL Development Rationale Potentially enhance response durability and decrease chemotherapy use, thus providing a more tolerable and durable option Potentially provides R/R patients a treatment option that is tolerable and efficacious where there are limited options 1 EvaluatePharma, ACS, consulting engagements with Health Advances and Clearview. 2 Standard of care (SOC) for 1L patients with CD30+ disease is brentuximab vedotin +/- chemotherapy and for CD30- patients it is the CHOP chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) Germany, Italy, France, and Spain (EU4); peripheral t-cell lymphoma (PTCL); relapsed refractory (R/R); standard of care (SOC) 1L 2L+ ~16,000 ≤12,000 U.S. + EU4 + UK Addressable Patients (2024)1 Treatment Line © 2025 C4 Therapeutics, Inc. NHL 18

 
2 Cemsidomide Has a Strategic Path to Become a Potential Backbone Therapy for MM and NHL Across Various Lines of Treatment Dex combination in late-line MM In combination with MM agents in 2/3L Establish as backbone treatment across MM (1L+) • Highest unmet patient need opportunities in a growing population • Fastest path to label • Combination strategies with other MM agents to expand to 2L+ MM • Combine with standard of care in front-line NHLs • Maximize broad applicability • Drive revenue growth Monotherapy in 2L+ PTCL Expand to 1L PTCL in combination with SOC Establish as backbone treatment across NHL Multiple myeloma (MM); non-Hodgkin’s lymphoma (NHL); peripheral T-cell lymphoma (PTCL); standard of care (SOC) 1 3 © 2025 C4 Therapeutics, Inc. 19

 
CFT8919 EGFR L858R Degrader Non-Small Cell Lung Cancer

 
CFT8919 Is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R With Potential to Improve Outcomes for NSCLC Patients CFT8919 Orthosteric Inhibitor Potential Degrader Advantages of CFT8919: CFT8919 exploits an allosteric binding site created by the L858R mutation, thereby avoiding resistance mutations to the orthosteric site Potent and selective against L858R regardless of secondary mutations with potential for more durable activity in this setting Does not hit wild-type, potentially resulting in better tolerability Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) Current Approved EGFR Inhibitors Have Limitations: • Patients become refractory due to secondary mutations • NSCLC patients with L858R have inferior clinical outcomes • Toxicities associated with inhibition of wild-type EGFR limit tolerability © 2025 C4 Therapeutics, Inc. 21

 
CFT8919 Binds to Allosteric Site, Avoiding Impact of L858R Non-classical Co-mutations in the Orthosteric Binding Pocket Sources: 1. From Black Diamond’s analyses of 94,939 sequencing reports from treatment naive NSCLC (Guardant Health) presented at AACR 2024 (https://blackdiamondtherapeutics.com/assets/files/AACR_2024__BDTX-1535_FINAL_Presentation_20240405.pdf) 2. Gitenbeek, et al. 2023 Progression free survival (PFS) CFT8919 binds to the allosteric site, potentially avoiding the impact of non-classical co- mutations with L858R, where inhibitors demonstrate lower PFS in this patient population than those with EXON 19 deletion 1 2 Overall survival by type of mutation in patients with Stage IV EGFR mutated NSCLC and brain metastasis who received first-line treatment with osimertinib EGFR-L858R Tumors More Frequently Co-express Non-classical EGFR Mutations Before Exposure to EGFR TKI1 Patients with L858R Do Less Well on Osimertinib Therapy vs Ex19del © 2025 C4 Therapeutics, Inc. 22

 
Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 CFT8919 Is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models Source: C4T data on file; Presented at Keystone Symposium 2021 (https://c4therapeutics.com/wp-content/uploads/Preclinical-Evaluation-of-CFT8919-as-a-Mutant-Selective-Degrader- of-EGFR-with-L858R-Activating-Mutations-for-the-Treatment-of-Non-Small-Cell-Lung-Can.pdf) Investigational new drug application (IND) EGFR-L858R EGFR-L861Q 0 5 10 15 0 500 1000 1500 2000 Days of Treatment B a F 3 E G F R L 8 5 8 R /T 7 9 0 M /C 7 9 7 S T u m o r v o lu m e ( m m 3 ) Vehicle PO BID Osimertinib 25 mpk PO QD CFT8919 10 mpk PO BID CFT8919 25 mpk PO BID CFT8919 50 mpk PO BID Specific for EGFR Exon 21 Mutants Active in Setting of EGFR C797S © 2025 C4 Therapeutics, Inc. 23

 
Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 Mean plasma concentration shown for n > 2 CFT8919 Demonstrates Activity in Brain Metastasis Model Source: C4T data on file; presented at TPD Summit 2021 (https://c4therapeutics.com/wp-content/uploads/C4_CFT8919_TPD_Summit_Presentation.pdf) By mouth (PO); twice daily (BID) 4 6 8 10 12 10 100 1000 10000 Time (hr) C F T 8 9 1 9 c o n c e n tr a ti o n in p la s m a ( n g /m l) a n d t u m o r (n g /g ) Plasma Tumor in brain Plasma clearance t1/2 = 3.1 hrs 0 5 10 15 0 200 400 600 Study Day B L I (p h o to n s /s × 1 0 6 ) Vehicle CFT8919 (50mg/kg PO BID) 0 5 10 15 -20 -10 0 10 20 Study Day B o d y W e ig h t C h a n g e ( % ) * *Body weight loss due to tumor burden 50 mg/kg single dose PO Mean Plasma & Tumor Concentration In vivo Efficacy In vivo Body Weight Change © 2025 C4 Therapeutics, Inc. 24

 
CFT8919 Has the Potential to Address Multiple Opportunities with High Unmet Needs CFT8919’s Fastest Path to Market Is in 2L+ With Potential to Expand Into Front-Line Development Rationale: • Fast path to market • Lack of therapies after patients relapse with secondary mutation (i.e., C797S) 2L+ Development Rationale: • Large patient opportunity • Potential to increase responses and durability in L858R patients Front-line Dose escalation in Greater China is advancing; C4T to utilize data to inform ex-China clinical development 2024 Annual Incidence of EGFR L858R Mutated NSCLC1: • U.S.: ~17,000 • China: ~189,000 • EU4 + UK: ~13,000 1 EvaluatePharma (accessed on 1/10/25), consulting engagements with Health Advances and Clearview. Germany, Italy, France, and Spain (EU4) © 2025 C4 Therapeutics, Inc. 25

 
Prioritized Portfolio with Multiple 2025 Milestones © 2025 C4 Therapeutics, Inc. Cemsidomide IKZF1/3 2Q 2025: Completed Phase 1 dose escalation in MM 3Q 2025: Present data from completed Phase 1 dose escalation in MM 4Q 2025: Complete Phase 1 dose escalation in NHL and present data 2H 2025: Open expansion cohort(s) in PTCL in the ongoing Phase 1/2 trial 2025: Enable initiation of the next phase of clinical development for cemsidomide with new studies expected to initiate in early 2026 CFT8919 EGFR L858R Year-end 2025: Utilize data from Phase 1 dose escalation trial in Greater China to inform ex-China clinical development 2Q 2025: Advanced two programs to preclinical milestones through the Roche collaboration 2025: Present and publish preclinical work from internal pipeline and TORPEDO platform 2025: Advance internal and collaboration programs to key discovery milestones Discovery Multiple myeloma (MM); peripheral T-cell lymphoma (PTCL), a subtype of NHL 26 2Q 2025: Complete monotherapy Phase 1 dose escalation trial in BRAF V600 mutant solid tumors 2Q 2025: Generate data from Phase 1 cohorts evaluating CFT1946 as a monotherapy in melanoma, in combination with trametinib in melanoma, and in combination with cetuximab in CRC to define and enable next phase of development CFT1946 BRAF V600 Mutant